Purpose In this preclinical study, we examined the biodistribution of hypericin formulated as its water-soluble PVP-hypericin complex in the diVerent layers (urothelium, submucosa, muscle) of a normal rat bladder and a rat bladder bearing a malignant urothelium composed of syngeneic AY-27 tumor cells. The results were compared with the biodistribution of hexaminolevulinate (HAL)-induced protoporphyrin IX (PpIX). Methods Freshly prepared PVP-hypericin and HAL solutions were instilled in both normal as well as tumor-bearing rat bladders. Following instillation, bladders were removed and snap frozen in liquid nitrogen. Fluorescence of PVPhypericin or PpIX-induced HAL was measured in the bladder layers and quantiWed using image analysis software. Results The results of these experiments show that PVPhypericin (30 M) accumulated about 3.5-fold more in malignant urothelial tissue when compared to normal urothelium, whereas PpIX accumulated to the same extent in malignant and normal urothelium, both after intrabladder instillation of 8 or 16 mM HAL. Besides, PVP-hypericin and PpIX accumulated selectively in the urothelium with a tumor-to-muscle ratio of 30.6 for PVP-hypericin and 3.7-8.3 for 16 and 8 mM HAL, respectively. Conclusions This study shows that PVP-hypericin appears to have great potential as a photodynamic agent against non-muscle-invasive bladder cancers after intravesical administration, with a limited risk of aVecting the deeper layers of the bladder.
Introduction
Urinary bladder cancer is the Wfth most frequent type of cancer in Western world [1] . When Wrst diagnosed, 75-85% of these bladder tumors are staged as non-muscleinvasive bladder cancers (NMIBC), which are generally treated by transurethral resection with or without adjuvant intravesical chemotherapy or immunotherapy [2, 3] .
During the last decade, several compounds have been tested for their capacity to photodiagnose eYciently malignant bladder lesions, and by doing so to reduce the amount of recurrences after transurethral resection of the bladder [4, 5] . One of the compounds used is hypericin, a Xuorescent photosensitizer that belongs to the chemical class of hydroxylated phenantroperylenequinones [6, 7] . After intrabladder instillation in patients suspected of having bladder cancer, hypericin showed a very good sensitivity and speciWcity for detecting NMIBC, including carcinoma in situ (CIS) [8] [9] [10] . The Wnding that hypericin is selectively taken up by urothelial tumor cells and not by normal cells is also supported by clinical studies using Xuorescence cytology [11, 12] .
In water, hypericin forms aggregates, thereby loosing its spectroscopic and tumor-selective properties [13] . In previous studies, this problem was overcome by including plasma proteins like human serum albumin (HSA) into the formulation to which hypericin adsorbs [8, 9] . More recently, with the intention to avoid the presence of proteins in the bladder instillation Xuid, a novel formulation was developed based on a water-soluble complex formed between hypericin and polyvinylpyrrolidone (PVP) [14, 15] .
5-Aminolevulinic acid (5-ALA) is another compound that is being used for Xuorescence cystoscopy of the bladder. Its use in urology was Wrst described by Leveckis et al. [16] . Exogenous administration of 5-ALA induces a transient rise in the cellular concentration of the Xuorescent PpIX, which is more pronounced in neoplastic cells than in normal cells [17, 18] . An ester precursor of 5-ALA, i.e., hexaminolevulinate (HAL), provides an even better selectivity and brighter Xuorescence when compared to the parent compound. Using Xuorescence cystoscopy in combination with intrabladder HAL, it was shown that 28% more patients with CIS were identiWed than with the standard cystoscopy method [19] . Hexaminolevulinate (Hexvix ® , Photocure ASA) has recently obtained a marketing authorization in 27 European countries, including Norway and Iceland, for the improved detection of superWcial bladder cancer [20] .
Hypericin and ALA-induced PpIX do not only exhibit red Xuorescence upon blue light irradiation, both compounds are also potent photosensitizers and hence could be useful in the photodynamic therapy (PDT) of NMIBC after intrabladder instillation [21] [22] [23] . PDT for cancer involves the local or systemic administration of a photosensitizer followed by local irradiation of the tumor tissue with non-thermal visible light of a speciWc wavelength. The local generation of ROS (reactive oxygen species) by the irradiated photosensitizer results in tumor destruction [7, 24] .
Anticipating the clinical use of PVP-hypericin in the therapeutic management of NMIBC, it is essential to understand the selectivity of the accumulation of the photosensitizer into urothelial malignant lesions. In order to avoid any damage, it is critical that the compound does not accumulate substantially into the deeper layers of the bladder wall, especially in the detrusor muscle.
This preclinical study examined the biodistribution of hypericin formulated as its water-soluble PVP-hypericin complex (hereafter called PVP-hypericin) in the diVerent layers (urothelium, submucosa, muscle) of a normal rat bladder and a rat bladder bearing a malignant urothelium composed of syngeneic AY-27 tumor cells [25] . The results were compared with the outcome using HAL in similar in vivo conditions. As there is a very limited penetration into the deeper layers of the bladder, we anticipate that PVPhypericin is a safe compound when it will be used for intravesical instillation followed by whole bladder wall photodynamic therapy.
Materials and methods

Animals
For all experiments, female Fisher rats (F-344), weighing a minimum of 160 g, were used (Charles River Laboratories, Lyon, France). Rats were provided with purine chow and water ad libitum. All animal procedures were performed in compliance with national and European regulations and were approved by the animal care and ethics committee of the Katholieke Universiteit Leuven.
Preparation of cells for tumor implantation
AY-27 cells, originally developed by Dr. S. Selman and Dr. J. Hampton (Ohio Medical College, USA), were kindly provided by Dr. D. Notter (Université henri Poincare, Nancy, France). Cells were cultured in 175-cm 2 tissue culture Xasks at 37°C in a humidiWed atmosphere containing 5% CO 2 and 95% air in minimum essential medium (MEM) with Earle's salts containing 2 mM L-glutamine, 1% antibiotic/antimycotic solution, 1% non-essential amino acids, tyrosine (60 g/ml) (Eli Lilly, Brussels, Belgium), and 10% fetal calf serum (FCS). All cell culture medium compounds were purchased from Invitrogen (Merlebeke, Belgium).
AY-27 cells were cultured until conXuency and then incubated for 30 min with 20 M green Xuorescent cell tracker 3,3Ј-dioctadecyloxacarbocyanine perchlorate (DiO). DiO was purchased from Molecular Probes Inc. (Eugene, OR, USA) and stored as a 20 mM stock solution in DMSO at ¡20°C. Just before use, the stock solution was diluted in MEM to obtain a concentration of 20 M. Afterward, cells were washed twice with PBS (pH 7.4), trypsinized, and collected after centrifugation (2000 rpm, 5 min, Jouan B3.11; St. Nazaire, France). Cells were counted using a Coulter Z1 particle counter (Coulter Electronic, Luton, UK) and resuspended in cell culture medium to obtain a concentration of 4 £ 10 6 cells/0.3 ml.
Tumor model
The technique used for tumor implantation was described previously ( [26] with modiWcation). Animals were anesthetized with an intraperitoneal injection of 45 mg/kg sodium pentobarbital (Nembutal) and placed on supine position on an animal board kept at 25°C. Bladders were catheterized via the urethra using a plastic 18-gauge intravenous catheter. Subsequently, the bladder mucosa was mildly disrupted using a wash with 0.3 ml of 0.1 N HCl for 20 s, followed by neutralization with the same quantity and strength of NaOH for 20 s. The bladder was then washed several times thoroughly with PBS. AY-27 cells (4 £ 10 6 cells in 0.3 ml of medium) loaded with DiO were instilled into the bladder via the catheter and maintained in the bladder for at least 1 h. Rats were turned by 45° every 15 min to allow equal exposure of tumor cells to the entire bladder wall. Thereafter, the cannula was removed, and the rats were allowed to void spontaneously. Animals were used for bladder wall distribution studies of the photosensitizers 3 days later.
Intrabladder instillation of PVP-hypericin and HAL Rats were anesthetized with sodium pentobarbital (Nembutal, 45 mg/kg, i.p.), and after catheterization, 0.3 ml of a freshly prepared PVP-hypericin instillation Xuid (30 M in 0.9% NaCl) (Provided by Sanochemia Pharmazeutika AG) or HAL (8 and 16 mM, prepared in phosphate buVered saline according to [27] ) (GE-Healthcare) was instilled in normal and in tumor-bearing bladders for 2 h (n = 6 per condition). Control animals (n = 3) were instilled with saline only. Afterward, bladders were removed, cut open, and immediately transferred into Tissue Tek embedding medium (Miles Inc., Elkhart, IN, USA) and immersed in liquid nitrogen. Cryostat microtomy was performed to cut 5-m sections.
Imaging and quantiWcation of Xuorescence
Imaging and quantiWcation of Xuorescence in sections of normal bladder and tumor-bearing bladders were performed by the use of a Xuorescence microscope equipped with image analysis software. The microscope consisted of an Axioskop 2 plus Xuorescence microscope (Carl Zeiss, Göttingen, Germany) illuminated by a 100-W mercury lamp. Fluorescence images were acquired using a lightsensitive charge-coupled device (CCD) digital camera (AxioCam HR, Carl Zeiss, Göttingen, Germany). For Xuorescence quantiWcation, a KS imaging software system (Carl Zeiss, Vision GmbH, Hallbergmoos, Germany) was used. Throughout the study parameters such as objective lenses, excitation and emission Wlters and exposure time were kept constant to maintain uniformity.
The presence of tumor tissue was conWrmed through the Xuorescence detection of DiO, using a Wlter set consisting of a 450-490 nm band-pass excitation Wlter and a 515-565 nm band-pass emission Wlter. For Xuorescence imaging of PVP-hypericin, a Wlter set with a 510-560 nm band-pass excitation Wlter and a 590 nm long-pass emission
Results
In the present study, the biodistribution of both PVP-hypericin and HAL-induced PpIX was compared in normal and tumor-bearing rat bladders. After instillation, the induced Xuorescence was measured in the diVerent layers of the bladder (urothelium, submucosa, muscle) and further quantiWed using image analysis software. Figures 1 and 2 show typical Xuorescence micrographs of 5-m bladder sections after instilling PVP-hypericin (Fig. 1a, c) or HAL (Fig. 2a, c) in normal (Figs. 1a, 2a) or tumor-bearing bladders (Figs. 1c, 2c) . AY-27 cells could easily be visualized by pre-incubating them in vitro with the green Xuorescent carbocyanine dye DiO, and interestingly, a good correlation between areas consisting of malignant urothelium loaded with the green Xuorescent DiO and the localization of PVP-hypericin-or PpIX-related red Xuorescence was found (Figs. 1e, f, 2e, f) .
Overall, PVP-hypericin-related Xuorescence was strong, whereas accumulated PpIX showed a weaker Xuorescence signal. Because of this diVerence, a lower gain of sensitivity (gain 2) and a higher gain of sensitivity (gain 3) were used for PVP-hypericin and PpIX imaging, respectively.
In comparison with the epithelial cell layers visualized by H&E staining (Fig. 1b) , it can be seen that PVP-hypericin penetrated the normal urothelium only very limitedly. Only the Wrst two epithelial cell layers show bright Xuorescence, whereas the deeper layers virtually do not exhibit any Xuorescence signal. On the other hand, PVP-hypericin migrated well throughout all cell layers of the malignant urothelium, resulting in a uniform distribution of the compound in all cell layers of the epithelium (Fig. 1d) .
Conversely, HAL-induced PpIX displayed a homogeneous distribution in both, malignant and normal urothelium (Fig. 2a, c) .
QuantiWcation of the Xuorescence signal in sections of normal and tumor-bearing bladders after PVP-hypericin or HAL treatment revealed that PVP-hypericin (Fig. 3a) accumulated on average about 3.5-fold more in malignant urothelial tissue when compared to normal urothelium, whereas PpIX accumulated to the same extent in malignant and normal urothelium, both after intrabladder instillation of 8 or 16 mM HAL (Fig. 3b, c) . In order to assess the selectivity of accumulation of PVP-hypericin and PpIX in the urothelium of normal bladders and tumor bladders, (1) the ratio of the relative Xuorescence present in the urothelium (F U ) to the one present in the submucosa (F SM ) and (2) the ratio of the relative Xuorescence present in the urothelium (F U ) to the one present in the muscle (F M ) were calculated. The results are presented in Table 1 and show that both PVP-hypericin and PpIX accumulated selectively in the urothelium with a tumor-to-muscle ratio of 30.6 for PVP-hypericin and 3.7-8.3 for 16 and 8 mM HAL, respectively.
Discussion
In the present in vivo study, the biodistribution of PVPhypericin and HAL-induced PpIX in both healthy rat bladders and in an orthotopic rat bladder tumor model was compared. For that purpose, we instilled rats intravesically with PVP-hypericin (30 M) or HAL (8, 16 mM) 3 days after tumor inoculation with concentrations that correspond to the ones typically used in the urological clinic [5, 8, 9, [28] [29] [30] . The results show that administration of either of the compounds resulted in an increased uptake (PVPhypericin) or production (PpIX) of the photosensitizers in normal or malignant urothelium when compared with the deeper tissue layers, i.e. submucosa and muscle layer.
The uptake of 5-ALA or its derivative HAL and subsequent conversion to the photoactive compound PpIX, depends on a broad range of metabolic and tissue-speciWc factors [18] , but also on the administration route, concentration, and instillation time [31] . In this study, a similar procedure was applied that was used before by another group investigating the biodistribution of HAL-induced PpIX in the orthotopic rat bladder tumor model for the Wrst time [27] . Our results are in line with the published data with regard to the similar PpIX accumulation in normal and tumor urothelium that are seen when 8 or 16 mM HAL is instilled [27] . In contrast, the tumor-to-muscle ratio was previously found equal at both concentrations, whereas in our study, the tumor-to-muscle ratio is twice as high when using 8 mM HAL when compared to 16 mM HAL.
A similar PpIX Xuorescence in malignant urothelium after 8 and 16 mM HAL administration does, however, not necessarily guarantee a similar PDT eYcacy. For instance, PDT after 16 mM HAL resulted mostly in bladder wall necrosis without tumor eradication, whereas with 8 mM HAL and the same light conditions used, there was eVective tumor damage without any eVect on the bladder wall [27] .
Of interest, a follow-up study by the same group using a gross tissue extraction method indicated that after 8 mM HAL, the PpIX concentration in tumor bladders was signiWcantly higher than with 16 mM HAL [32] , and it was concluded that PpIX Xuorescence as measured by Xuorescence microscopy does not always mirror linearly drug concentrations. Besides, also the subcellular localization of PpIX critically depends on the concentration of HAL instilled. Importantly, this localization aVects the damage to speciWc cellular organelles and therefore the PDT eYcacy [32] . Hence, predicting the photodynamic therapeutic outcome based exclusively on the HAL-induced PpIX Xuorescence observed appears to be diYcult. This is especially problematic when it comes to potentially photo-active amounts of photosensitizer present in the detrusor muscle resulting in Wbrotic and contracted bladder with upper tract obstruction [33, 34] . For obvious reasons, these adverse eVects should be thoroughly avoided. The biodistribution of PVP-hypericin in the diVerent layers of the orthotopic tumor-bearing rat urinary bladder correlates well with the one observed in similar conditions when hypericin is formulated in the presence of human serum albumin (HSA) [35] . The Xuorescence intensity ratios of the bladder urothelial tumor to both submucosa and muscle are comparable in both studies. As a consequence, it can be expected that the outcome of whole bladder wall PDT in an in vivo model will largely coincide with the results previously obtained using HSA-hypericin [36] . In contrast with HAL, when using PVP-hypericin, there seems to exist a good correlation between the Xuorescence present in the diVerent layers and the local damage photodynamically induced.
An interesting observation is the fact that HSA-hypericin was not selectively taken up by malignant when compared to normal urothelium [35] , whereas PVP-hypericin in this study is taken up about a 3-to 4-fold more in malignant tissue than in benign urothelium. Presently, we cannot account for this diVerence, but deWnitely the present preclinical Wndings with PVP-hypericin support very well the clinical results obtained with both HSA-and PVP-hypericin that detect NMIBC with a high sensitivity and good speciWcity [8] [9] [10] 28] . For example, in case of PVP-hypericin used for the Xuorescence-based diagnosis of bladder cancer in patients, a sensitivity ranging from 85% (dysplasia) to 100% (CIS, T1 and T2) and a speciWcity of 53% was found [28] .
Whether the diVerence in accumulation of PVP-hypericin between malignant tissue and benign urothelium will also result in a diVerential PDT eVect is yet unknown. However, even if not entirely the case, it is known that PDTinduced urothelial damage regenerates in a short time period without signiWcant alterations to the bladder wall [37, 38] .
In conclusion, we have shown that after instillation of a normal and an orthotopic tumor-bearing rat urinary bladder, PVP-hypericin and HAL-induced PpIX are selectively present in the bladder urothelial tumors. Overall, the accumulation in the urothelium versus the underlying tissues is much better for PVP-hypericin than for PpIX. The restrictive distribution in the urothelial tumor suggests that by using appropriate light doses, PDT with PVP-hypericin should produce a selective urothelial tumor destruction without causing damage to the muscle layer. Besides being an eVective diagnostic tool, PVP-hypericin therefore appears to have great potential as a photodynamic agent against non-muscle-invasive bladder cancers.
